Employees: 301
Size Polynovo (PNV.AX) is an Australia Health Care company (Biotechnology) with a market value of $388M, the 285th largest of 317 Australia companies the cockpit tracks. Shares closed at A$0.84 on 18 Nov 2026.
Performance Over six months the shares fell 33.9%, against -31.0% for the median peer and +1.2% for the Australia market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue grew 12.9% over the last twelve months (peer median +5.5%); the operating margin is 5.0% (peer median -4.3%).
Valuation It trades at 84.0× forward earnings against a peer median of 16.2× (most expensive of 4).
Price implies For today's price to make sense, revenue must grow about 52% a year for seven years (Req g). Recent delivered growth is +38%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 7.2 points below its cost of capital (14.1% WACC).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | A$144M | A$144M | A$127M | A$103M | A$65.2M |
| Revenue growth | — | +13% | +23% | +58% | — |
| Gross profit | A$47.0M | A$47.0M | A$44.8M | A$36.1M | A$19.3M |
| EBITDA | A$9.86M | A$13.9M | A$7.81M | A$3.90M | -A$3.90M |
| Net income | A$7.34M | A$7.34M | A$13.2M | A$5.26M | -A$4.92M |
| Free cash flow | A$9.45M | A$9.45M | -A$10.1M | A$2.19M | -A$7.46M |
| Capital expenditure | A$13.8M | A$13.8M | A$13.9M | A$2.90M | A$1.53M |
| Total debt | n/a | A$17.6M | A$17.1M | A$15.4M | A$16.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PNV.AX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.2% | -13.7% | 8th highest of 21 |
| 6-month return | -33.9% | -31.0% | 8th lowest of 21 |
| Distance from 52-week high | -35.2% | -47.6% | 7th highest of 21 |
| Revenue growth (TTM) | +12.9% | +5.5% | 7th highest of 16 |
| Operating margin | 5.0% | -4.3% | 7th highest of 16 |
| Forward P/E | 84.0× | 16.2× | most expensive of 4 |
| Growth the price implies (Req g, 7 yrs) | 51.9% | -7.3% | most demanding of 5 |
| Growth delivered (Del g) | +37.6% | +103.1% | 3rd highest of 5 |
| Hurdle (Req g minus delivered) | +14.3 pp | -97.6 pp | 3rd least demanding of 5 |
| ROIC minus cost of capital | -7.2 pp | -9.2 pp | 6th highest of 16 |
| EV / EBITDA | 57.0× | 5.2× | most expensive of 6 |
| Net debt / EBITDA | -1.8× | -2.6× | 2nd most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Polynovo PNV.AX | Australia | $388M | -34% | +13% | 5% | 84.0× | 51.9% | +37.6% |
| Beijing Kawin Technology Share-Holding 688687.SS | China | $391M | -20% | +6% | -2% | 16.2× | 36.6% | +8.9% |
| Hubei Goto Biopharm 300966.SZ | China | $386M | -16% | +6% | -10% | n/a | n/a | n/a |
| Alector ALEC | United States | $383M | +21% | +151% | 25% | n/a | n/a | n/a |
| Wuhan Hiteck Biological Pharma 300683.SZ | China | $395M | -41% | -30% | -27% | n/a | n/a | n/a |
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $396M | -33% | n/a | n/a | 26.2× | n/a | n/a |
| PureTech Health PRTC.L | United Kingdom | $378M | -15% | -4% | -1,617% | n/a | n/a | n/a |
| Shanghai Shen Lian Biomedical 688098.SS | China | $402M | -22% | -17% | -16% | n/a | n/a | n/a |
| Jacobio Pharmaceuticals 1167.HK | Hong Kong | $404M | -24% | +286% | 68% | 5.7× | -18.8% | -36.1% |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $370M | -31% | 0% | -4% | n/a | n/a | n/a |
| Hanx Biopharmaceuticals (Wuhan) 3378.HK | Hong Kong | $409M | -24% | n/a | n/a | n/a | n/a | n/a |
| Edding Genor 6998.HK | Hong Kong | $410M | -35% | +1,418% | 26% | n/a | -15.3% | +197.3% |
| Onconic Therapeutics 476060.KS | South Korea | $368M | -49% | +179% | 21% | n/a | 0.6% | +725.2% |
| Shanghai Obio Technology (Group) 688238.SS | China | $414M | -5% | +20% | -79% | n/a | n/a | n/a |
| Eupraxia Pharmaceuticals EPRX.TO | Canada | $416M | +1% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Serum Bio-Technology 688163.SS | China | $416M | -34% | -1% | 26% | n/a | n/a | n/a |
| Contineum Therapeutics CTNM | United States | $363M | -31% | n/a | n/a | n/a | n/a | n/a |
| G2GBIO 456160.KS | South Korea | $416M | -53% | -45% | -2,884% | n/a | n/a | n/a |
| Candel Therapeutics CADL | United States | $417M | -31% | n/a | n/a | n/a | n/a | n/a |
| Rznomics 476830.KS | South Korea | $418M | -76% | -65% | -1,112% | n/a | n/a | n/a |
| CorMedix CRMD | United States | $358M | -43% | +92% | 39% | n/a | n/a | n/a |